Hye-Young Lee
Hye-Young Lee has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ari Ahn
Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea
1 shared publication - Chan-Jeoung Park
Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, South Korea
1 shared publication - Dong Ock Lee
Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea
1 shared publication - Eul-Ju Seo
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
1 shared publication - Eun Sook Lee
National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea
1 shared publication - Eun-Hae Cho
Genome Research Center, GC Genome, Yongin, Korea
1 shared publication
Latest Publications
- Open Access
- 6 August 2020
- Published by Wiley in Cancer Science
- Vol. 111 (10) , 3912-3925
Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer
The use of multigene panel testing for patients with a predisposition to breast/ovarian cancer is increasing as the identification of variants is useful for diagnosis and disease management. We identified pathogenic and likely pathogenic (P/LP) variants of high‐and moderate‐risk genes using a 23‐gene germline cancer panel in 518 patients with hereditary breast and ovarian cancers (HBOC). The frequency of P/LP variants was 12.4% (64/518) for high‐ and moderate‐penetrant genes, namely, BRCA2 (5.6%), BRCA1 (3.3%), CHEK2 (1.2%), MUTYH (0.8%), PALB2 (0.8%), MLH1 (0.4%), ATM (0.4%), BRIP1 (0.4%), TP53 (0.2%), and PMS2 (0.2%). Five patients possessed two P/LP variants in BRCA1/2 and other genes. We also compared the results from in silico splicing predictive tools and exon splicing patterns from patient samples by analyzing RT‐PCR product sequences in six P/LP intronic variants and two intronic variants of unknown significance (VUS). Altered transcriptional fragments were detected for P/LP intronic variants in BRCA1, BRIP1, CHEK2, PARB2, and PMS2. Notably, we identified an in‐frame deletion of the BRCA1 C‐terminal (BRCT) domain by exon skipping in BRCA1 c.5152+6T>C—as known VUS—indicating a risk for HBOC. Thus, exon splicing analysis can improve the identification of veiled intronic variants that would aid decision making and determination of hereditary cancer risk.
- 6 August 2020
- Published by Wiley in Cancer Science
- Vol. 111 (10) , 3912-3925
Open AccessExon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer
The use of multigene panel testing for patients with a predisposition to breast/ovarian cancer is increasing as the identification of variants is useful for diagnosis and disease management. We identified pathogenic and likely pathogenic (P/LP) variants of high‐and moderate‐risk genes using a 23‐gene germline cancer panel in 518 patients with hereditary breast and ovarian cancers (HBOC). The frequency of P/LP variants was 12.4% (64/518) for high‐ and moderate‐penetrant genes, namely, BRCA2 (5.6%), BRCA1 (3.3%), CHEK2 (1.2%), MUTYH (0.8%), PALB2 (0.8%), MLH1 (0.4%), ATM (0.4%), BRIP1 (0.4%), TP53 (0.2%), and PMS2 (0.2%). Five patients possessed two P/LP variants in BRCA1/2 and other genes. We also compared the results from in silico splicing predictive tools and exon splicing patterns from patient samples by analyzing RT‐PCR product sequences in six P/LP intronic variants and two intronic variants of unknown significance (VUS). Altered transcriptional fragments were detected for P/LP intronic variants in BRCA1, BRIP1, CHEK2, PARB2, and PMS2. Notably, we identified an in‐frame deletion of the BRCA1 C‐terminal (BRCT) domain by exon skipping in BRCA1 c.5152+6T>C—as known VUS—indicating a risk for HBOC. Thus, exon splicing analysis can improve the identification of veiled intronic variants that would aid decision making and determination of hereditary cancer risk.
- Open Access
- 1 September 2019
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 39 (5) , 496-498
Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma
Lee HY, et al. Ann Lab Med. 2019 Sep;39(5):496-498. https://doi.org/10.3343/alm.2019.39.5.496
- 1 September 2019
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 39 (5) , 496-498
Open AccessTwo Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma
Lee HY, et al. Ann Lab Med. 2019 Sep;39(5):496-498. https://doi.org/10.3343/alm.2019.39.5.496